dsm-firmenich unveils advanced CBD drug product intermediate

The IP-protected CBD intermediate brings superior functionality allowing for a higher drug loading compared to currently commercially available products, paving the way for oral dosage forms with enhanced bioavailability. This will enable the development of more convenient and patient-friendly dosage forms – like tablets, including orally disintegrating tablets (ODTs) or chewables – making CBtru a significant advancement in cannabinoid innovation with the capacity to transform CBD-based therapies.

Pioneering a new frontier in CBD drug development

Existing CBD-based medicines exhibit limited oral bioavailability (as low as 6% in humans), and therefore efficacy, due to the poor solubility and absorption of cannabinoid molecules. Consequently, large doses of CBD are needed for therapeutic effectiveness and require administration via oil-based oral solutions, which can be inconvenient and unpleasant for patients to ingest. dsm-firmenich says its advanced formulated CBD drug product intermediate aims to address this challenge. It allows for higher active loading, improved stability and optimized pharmacokinetic performance, enabling the creation of more bioavailable and patient-friendly dosage forms.

A molecule that holds immense therapeutic potential

“We’re committed to elevating global patient health by unlocking new treatment possibilities and improving product acceptance and compliance. That’s why we have invested in CBD – a molecule that holds immense therapeutic potential, as evidenced by promising research and a shifting favorable regulatory environment,” said Athanasia Kanli, global business development manager for pharma at dsm-firmenich.

Leave a Reply

Your email address will not be published. Required fields are marked *